24-HOUR BLOOD PRESSURE MONITORING PARAMETERS AND THE NUMBER OF METABOLIC SYNDROME COMPONENTS
Abstract
Arterial hypertension (AH) is one of the most prevalent components of metabolic syndrome (MS). At the same time, AH is a major risk factor predicting the development and progression of cardiovascular disease. The available literature provides inconsistent evidence on the association between the number of present MS components, blood pressure (BP) levels, and disturbed circadian BP profile. This study demonstrated that a higher number of MS components is linked to a higher AH stage and higher mean levels of most circadian, daytime, and nighttime parameters of 24-hour BP monitoring. Moreover, there was a significant increase in the numbers of “non-dippers” (patients with inadequate nighttime BP reduction), which is associated with a higher risk of cardiovascular events.
About the Authors
Yu. V. Zhernakova
ФГУ Российский кардиологический научно – производственный комплекс МЗ и СР РФ Институт клинической кардиологии им. А. Л. Мясникова, отдел системных гипертензий, Москва
Russian Federation
Russian Federation
I. E. Chazova
ФГУ Российский кардиологический научно – производственный комплекс МЗ и СР РФ Институт клинической кардиологии им. А. Л. Мясникова, отдел системных гипертензий, Москва
Russian Federation
Russian Federation
S. P. Olimpieva
РГМУ им. Н. И. Пирогова, кафедра медицинской кибернетики и информатики медико-биологического факультета, Москва
Russian Federation
Russian Federation
V. V. Kilikovskyi
РГМУ им. Н. И. Пирогова, кафедра медицинской кибернетики и информатики медико-биологического факультета, Москва
Russian Federation
Russian Federation
References
1. Mancia G, Bombelli M, Corrao G. et al. Metabolic syndrome in thePressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: dailylife blood pressure, cardiac damage, and prognosis. Hypertension 2007; 49:40–47.
2. Ferrannini E, Natali A, Capaldo B. et al. Insulin resistance, hyperinsulinemia, and blood pressure: Role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension 30: 1144 –1149, 1997.
3. Ferrari P, Weidmann P. Insulin, insulin sensitivity and hypertension. J Hypertens 1990; 8: 491–500.
4. Muscelli E., Emdin M., Natali A. et al. Cardiac responses to insulin in vivo: influence of obesity. J Clin Endocrinol Metab 1998;83:2084–2090.
5. Anderson E. A., Hoffman R. P., Balon T. W. et al. Hyperinsulinemia produced both sympathetic neuronal activation and vasodilatation in normal humans. J Clin Invest 1991; 87:2246–52.
6. Rowe J. R., Young J. B., Minaker K. L. et al. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981;30:219–25.
7. Sims E. A., Danforth E., Norton E. S. et al. Endocrine and metabolic effects of experimental obesity in man. Rec Prog Harm Res 1973; 29 457–96.
8. Austin M. A., Hokanson J. E., Edwards K. L. Hypertriglyceridemia as a cardiovascular risk factor. Am. J. Cardiol. 1998; 81:7B-12B.
9. Filer J. S. Leptin resistance and obesity. Presented at the 60 th Scientific Sessions of the american diabetes association. June 13, 2000; San-Antonio, TEXAS.
10. Matsukawa T., Mano T., Ishii M. Elevated sympathetic nerve activity in patients with accelerated essential hypertension. J Clin Invest 1993; 92: 25–8.
11. Kamide K., Hori M., Zhu J. et al. Insulin-mediated growth in aortic smooth muscle and the vascular rennin-angiotensin system. Hypertension 1998; 32: 482–487.
12. Kopf D., Muhlen I., Kroning G. et al. Insulin sensitivity and sodium excretion in normotensive offspring and hypertensive patients. Metabolism 2001;50, N8: 929–935.
13. Mattiasson I, Berntrop K, Lindgarde F. Sodium-lithium countertransport and platelet cytosolic free calcium concentration in relation to peripheral insulin sensitivity in postmenopausal women. Clin Sci 1992; 83: 319–324.
14. European Society of Hypertension-European Society of Cardiology Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21: 1011 –1053, 2003.
15. Schillaci G, Pirro M, Vaudo G. et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 19: 1817 –1822, 2004.
16. McNeill AM, Rosamond WD, Girman CJ. et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28: 385 –390, 2005.
17. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: Findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 173: 309 –314, 2004.
18. Navarro J, Redón J, Cea-Calvo L. et al. Metabolic syndrome, organ damage and cardiovascular disease in treated hypertensive patients. The ERICHTA study. Blood Press. 2007;16 (1):20–7.
19. Иевлева Г. И., Тесля Е. Ф., Биктимирова Д. М. и др. Показатели суточного артериального давления у больных с метаболиче-ским синдромом. Клиническая медицина 2009;№ 6: с. 15–19.
20. Ahmet Soylu, Hakan Güleç, Yusuf İzzettin Alihanoğlu, et al. The effect of nondipper blood pressure pattern on target organ damage in patients with metabolic syndrome. Türk Kardiyol Dern Arş 2009; 37:454–460.
21. Cuspidi C., Meani S., Valerio C. et al. Metabolic syndrome score and ambulatory blood pressure in untreated essential hypertension. Blood Pressure Monitoring 2005 Aug;10 (4):175–80.
22. Mohammed O. Hassan, Deepali Jaju, Sulayma Albarwani et al. Non-dipping Blood Pressure in the Metabolic Syndrome Among Arabs of the Oman Family Study. Obesity 2007; 15: 2445–2453.
Review
For citations:
Zhernakova Yu.V., Chazova I.E., Olimpieva S.P., Kilikovskyi V.V. 24-HOUR BLOOD PRESSURE MONITORING PARAMETERS AND THE NUMBER OF METABOLIC SYNDROME COMPONENTS. Russian Journal of Cardiology. 2011;(6):25-30. (In Russ.)
Views:
358
Email this article 